CNBX
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.00 | $0 | -$30,549 |
| 2025 Q1 | -0.00 | $0 | -$47,408 |
| 2025 Q4 | 0.00 | $0 | -$28,545 |
| 2025 Q3 | -0.00 | $0 | -$52,019 |
| 2025 Q2 | -0.00 | $0 | -$51,664 |
| 2024 Q1 | -0.00 | $0 | -$39,077 |
| 2024 Q4 | -0.00 | -$17,570 | -$48,250 |
| 2024 Q3 | -0.00 | $17,570 | $225 |